<div>
  <ul>
    <li>
      <p>
        Glooko, a remote patient monitoring and diabetes care platform, has acquired French diabetes care platform DIABNEXT as part of its plans to
        <b> </b>
        expand its platform reach across the globe. This marks the company&rsquo;s second acquisition so far in 2022. It previously acquired xbird, an AI-powered diabetes care tool, in January 2022.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The French company&rsquo;s mobile app tracks and monitors patient diabetes data to support remote care. Following the acquisition, DIABNEXT&rsquo;s employees will join Glooko&rsquo;s Paris office, and Laurent Nicolas, the former CEO of DIABNEXT, will lead its operations in France as managing director.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market. The acquisition will help DIABNEXT scale its operations into more regions and expand its remote patient monitoring services.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://glooko.com/news_reg/glooko-acquires-diabnext-to-expand-diabetes-offerings-in-france/">
      Company press release
    </a>
  </p>
  <p>
    <a href="https://hitconsultant.net/2022/03/16/glooko-acquires-diabnext/">
      HIT Consultant
    </a>
  </p>
  <p>
    <a href="https://www.mobihealthnews.com/news/glooko-acquires-fellow-diabetes-management-company-diabnext-and-more-digital-health-briefs">
      Mobi Health News
    </a>
  </p>
</div>


Preventive Healthcare

Glooko acquires DIABNEXT to expand platform offering in France

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>Alex Therapeutics, a digital health provider, is partnering with Navamedic, a pharmaceutical company from Sweden, to create a companion app specifically designed to manage Parkinson's disease treatment. </p>
 <p>This application will offer patients who are taking Flexilev, a prescription medication for Parkinson's, assistance in managing their medication. This will augment the function of the OraFID dose dispenser, creating a unique combination to promote adherence to personalized treatment schedules. With its initial launch in Sweden, Norway, and Denmark planned within the next year, there are also plans for this app to be expanded globally in future.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//www.prnewswire.com/news-releases/pfizer-and-alex-therapeutics-announce-a-strategic-commercial-partnership-to-provide-evidence-based-digital-therapeutics-to-patients-starting-in-germany-301471350.html"> January 2022 </a> , the company partnered with Pfizer to develop a digital therapeutics (DTx) app to treat nicotine addiction. The company had also partnered with Vicore Pharma to develop a DTx for treating anxiety and depression in patients with idiopathic pulmonary fibrosis.</p>

Alex Therapeutics partners with Navamedic to develop Parkinson's disease companion app

<div>
 
 <p>The digital health company, Hinge Health, has launched Enso 3, an FDA-cleared device for pain relief. This wireless device employs electrical nerve stimulation as a non-invasive, non-addictive method for pain relief. Accessibility for new Hinge Health members will commence in 2025.</p>
 <p>New hardware with improved aesthetics and materials are featured in Enso 3, making it comfortable to wear during exercise or daily activities. The device offers new electric waveforms that are clinically proven and custom-made for various body parts and pain levels. It also has the capacity for future waveform releases through over-the-air software updates. Enso 3 is integrated with the Hinge Health app for member guidance and tracking progress. </p>
 
</div> <p><b>Analyst Quicktake:<br>
 </b> Hinge Health acquired Enso in <a href="https:<br>
//sp-edge.com/updates/2441"> March 2021 </a> for an undisclosed sum. At the time, Hinge Health intended to offer Enso’s device, together with Hinge’s digital musculoskeletal (MSK) solutions, to employers and health plans as an alternative to opioid pain medication.</p>

Hinge Health launches Enso 3 for musculoskeletal pain relief

<div>
 <p>Viome Life Sciences, a startup specializing in passive remote monitoring, has successfully secured USD 25 million in a Series D funding round. Key participants included prominent entities such as Khosla Ventures, Bold Capital, WRG Ventures, and Marc Benioff among others.</p>
 <p>This newly raised capital is intended to be allocated for the inception of a diagnostics division as well as the expansion of current solutions aimed at chronic diseases, cancer, and aging. As part of this strategic development, the company has welcomed Kal Raman to its executive team in the role of chief operating officer (COO). Boasting a diverse professional background, Raman has held notable positions at esteemed organizations such as Samsung, Groupon, and Amazon, where he worked under the direct leadership of Jeff Bezos.</p>
</div>

Viome raises USD 25 million in Series D funding to launch diagnostics division; appoints new COO

INCUMBENTS_PRESENT

<div>
 <p>Withings has attained FDA approval for Sleep Rx, a device testing for sleep apnea at home. This device aims to provide a more convenient and accurate method in diagnosing sleep apnea compared to traditional in-lab testing.</p>
 <p>Sleep Rx, a non-invasive device, can fit under any mattress and provide thorough analysis of sleep, breathing, and cardiovascular movements. The device is clinically validated for diagnosing sleep apnea and requires minimal setup.</p>
</div>

Withings receives FDA clearance for Sleep Rx home sleep apnea test

<div>
 <p>AppliedVR, a digital therapeutics company using VR, has been endorsed by commercial health insurer Highmark for their FDA-authorized VR device, RelieVRx, designed for treating chronic low-back pain.</p>
 <p>This endorsement means that more than 4 million Highmark members will have access to a 56-session, multimodal VR program to manage their chronic low-back pain at home. This is AppliedVR's first commercial payer partnership, which could lead to wider use of VR-based therapies in the healthcare industry.</p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 In <a href="https:<br>
//sp-edge.com/updates/17996"> April 2023 </a> , AppliedVR partnered with Lovell Government Services to broaden access to RelieVRx among federal healthcare providers. Further, in <a href="https:<br>
//www.prnewswire.com/news-releases/appliedvr-awarded-contract-with-vha-innovation-ecosystem-a-division-of-the-united-states-department-of-veterans-affairs-301698286.html"> December 2022 </a> , the company collaborated with the VHA Innovation Ecosystem to facilitate RelieVRx prescriptions at veteran facilities. These events highlight AppliedVR's strategic approach to expanding its market reach and integrating VR therapy into diverse healthcare settings.</p>

AppliedVR's RelieVRx for chronic low-back pain treatment receives coverage from Highmark

<div>
 <p>The Mayo Clinic announced a partnership with Exer AI, a pioneering artificial intelligence (AI) musculoskeletal (MSK) company, aiming to collaborate on the development of innovative AI solutions. The focus is on diagnosing and treating disorders related to the hand and wrist. This innovative combination of AI and computer vision platform could revolutionize remote and in-clinic checkups as well as telehealth assessments of hand and wrist conditions. The cutting-edge technology could analyze hand and wrist movements without the aid of sensors or wearing devices and can measure aspects such as total active motion and flexion/extension, enabling the diagnosis of conditions and provision of treatment suggestions.&nbsp;</p>
</div> <p><b>Analyst QuickTake</b> :<br>
 In <a href="https:<br>
//sp-edge.com/updates/31554"> July 2024 </a> , Mayo Clinic partnered with JOGO Health to develop tremor detection and management solutions using JOGO Health's digital platform, which combines wearable sensors and AI-driven technology. This underscores Mayo Clinic's strategic focus on advancing MSK and neuromuscular care solutions.</p>

Mayo Clinic partners with Exer AI to diagnose hand and wrist disorders using AI

<div>
 <p>Healthcare provider Aledade has initiated a service named Practice Health Recruiting Solution. The service aims to assist primary care practices in recruiting physicians, advanced practice providers, and other workforce members, in an attempt to rectify workforce challenges in primary care across the nation.</p>
 <p>The Practice Health Recruiting Solution simplifies the recruitment process from the beginning of opportunity intake to the sourcing and vetting of applicants for both clinical and non-clinical roles. The new solution also comprises candidates’ qualifications assessment, provision of guidance for hiring managers on strategies to attract and retain paramount talent, posting of job vacancies, and orchestration of the interview process.</p>
</div>

Aledade launches recruiting service for primary care practices

<div>
 <p>Oral Genome, a healthcare startup, has released saliva tests for the detection and prevention of oral diseases. These kits can be utilized at home or in clinical environments. They examine specific biomarkers connected to oral and systemic health like MMP-8, which is an initial marker for periodontal disease. Personalized reports from these tests aid in risk stratification and targeted interventions for ailments such as cavities, gum disease, and diabetes.</p>
 <p>In its main operation model, Oral Genome collaborates with dental institutions, public health entities, and insurance firms for the distribution of its tests. It is also branching out into D2C sales, enabling people to order kits online for private use. The business plan comprises of individual purchases as well as added-value online services.</p>
 </div>

Oral Genome launches saliva tests to detect oral diseases

<div>
 <p>Viz.ai, a California-based firm that specializes in AI-powered diagnostics and care coordination, has entered into a partnership with Cleerly, a company that diagnoses heart disease. The goal is to improve coordination of cardiovascular care.</p>
 <p>In the arrangement, Cleerly's FDA-approved AI software, used for analysis of coronary computed tomography angiography, will be integrated into Viz.ai's One platform. The collaboration is intended to improve heart disease detection and diagnosis, streamline the workflows of physicians, and enhance patient outcomes through AI-powered diagnostics for cardiovascular health. The combined solution will be accessible to over 1,600 hospitals that utilize Viz.ai's platform.</p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 This integration expands Viz.ai's AI platform, which includes features like ECG AI, echo AI, and chest CT visualization. Additionally, in 2022, the company partnered with Singapore-based software development company <a href="https:<br>
//sp-edge.com/updates/14273"> Us2.ai </a> to offer echocardiogram analysis within its platform.</p>

Viz.ai partners with Cleerly to enhance AI-powered cardiovascular care

<div>
 
 <p>The GUARD-AF study evaluated the effectiveness of Zio XT, a wearable heart monitor developed by iRhythm. Results showed that Zio XT improved AFib diagnoses by 52% compared to standard care, with 5.0% diagnosis rates versus 3.3% over an average of 15 months.</p>
 <p>Around 12,000 patients aged 70 or above from across the US participated in the study, which aimed to determine the device's efficiency in detecting AFib as compared to regular care. The Zio XT is considered a subtler, lighter alternative to traditional Holter monitoring, letting patients wear it for a fortnight for long-duration electrocardiogram monitoring.</p>
 
</div>

All Updates

Glooko acquires DIABNEXT to expand platform offering in France

Alex Therapeutics partners with Navamedic to develop Parkinson's disease companion app

Hinge Health launches Enso 3 for musculoskeletal pain relief

Viome raises USD 25 million in Series D funding to launch diagnostics division; appoints new COO

Withings receives FDA clearance for Sleep Rx home sleep apnea test

AppliedVR's RelieVRx for chronic low-back pain treatment receives coverage from Highmark

Mayo Clinic partners with Exer AI to diagnose hand and wrist disorders using AI

Aledade launches recruiting service for primary care practices

Oral Genome launches saliva tests to detect oral diseases

Viz.ai partners with Cleerly to enhance AI-powered cardiovascular care

iRhythm wearable heart monitor increases AFib diagnoses by 52%

Preventive Healthcare

Glooko acquires DIABNEXT to expand platform offering in France

Contact us